Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:12:45.692Z.
Calculation as of: 2026-10-06T22:12:45.692Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7cda135bbdc40ab96f6f5c38083b7dd78a9f140dcd8a254691991f8eaa2b9dc4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-10-20.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$17.39M
EV/EBIT Ratio
N/A
TTM Avg
64.12x
3Y Avg
126.81x
5Y Avg
126.81x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | $18.65M | N/A | N/A | N/A | N/A |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $19.77M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A | 64.12x | 126.81x | 126.81x |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A | 19.21x | 19.21x | 19.21x |
| PAVmed Inc. (PAVM)vs › | $17.07M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | N/A | N/A | N/A | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2025-10-20 | 6.50x |
| 2025-10-17 | 6.85x |
| 2025-10-16 | 5.84x |
| 2025-10-15 | 11.86x |
| 2025-10-14 | 8.40x |
| 2025-10-13 | 10.35x |
| 2025-10-10 | 12.62x |
| 2025-10-09 | 16.98x |
| 2025-10-08 | 15.15x |
| 2025-10-07 | 16.31x |
| 2025-10-06 | 19.89x |
| 2025-10-03 | 18.32x |
| 2025-10-02 | 4.29x |
| 2025-10-01 | 1.99x |
| 2025-09-29 | 1007.48x |
| 2025-09-26 | 1045.94x |
| 2025-09-25 | 1057.90x |
| 2025-09-24 | 972.44x |
| 2025-09-23 | 937.40x |
| 2025-09-22 | 836.54x |
| 2025-09-19 | 857.06x |
| 2025-09-18 | 797.23x |
| 2025-09-17 | 902.35x |
| 2025-09-16 | 1063.03x |
| 2025-09-15 | 1025.43x |
| 2025-09-12 | 1105.77x |
| 2025-09-11 | 1189.52x |
| 2025-09-10 | 1183.54x |
| 2025-09-09 | 1284.39x |
| 2025-09-08 | 1104.06x |
| 2025-09-05 | 1010.04x |
| 2025-09-04 | 1012.61x |
| 2025-09-03 | 1104.91x |
| 2025-09-02 | 1015.17x |
| 2025-08-29 | 962.18x |
| 2025-08-28 | 1037.39x |
| 2025-08-27 | 867.31x |
| 2025-08-26 | 700.65x |
| 2025-08-25 | 621.17x |
| 2025-08-22 | 607.49x |
| 2025-08-21 | 585.27x |
| 2025-08-20 | 586.98x |
| 2025-08-19 | 646.81x |
| 2025-08-18 | 659.63x |
| 2025-08-15 | 686.12x |
| 2025-08-14 | 686.12x |
| 2025-08-13 | 673.30x |
| 2025-08-12 | 622.88x |
| 2025-08-11 | 609.20x |
| 2025-08-08 | 628.86x |
| 2025-08-07 | 656.21x |
| 2025-08-06 | 663.90x |
| 2025-08-05 | 642.53x |
| 2025-08-04 | 658.77x |
| 2025-08-01 | 681.85x |
| 2025-07-31 | 686.98x |
| 2025-07-30 | 691.25x |
| 2025-07-29 | 725.44x |
| 2025-07-28 | 736.55x |
| 2025-07-25 | 720.31x |
| 2025-07-24 | 711.76x |
| 2025-07-23 | 694.67x |
| 2025-07-22 | 651.94x |
| 2025-07-21 | 651.94x |
| 2025-07-18 | 630.57x |
| 2025-07-17 | 633.99x |
| 2025-07-16 | 631.42x |
| 2025-07-15 | 639.97x |
| 2025-07-14 | 651.94x |
| 2025-07-11 | 651.08x |
| 2025-07-10 | 643.39x |
| 2025-07-09 | 631.42x |
| 2025-07-08 | 609.20x |
| 2025-07-07 | 605.78x |
| 2025-07-03 | 603.22x |
| 2025-07-02 | 593.82x |
| 2025-07-01 | 593.82x |
| 2025-06-30 | 600.66x |
| 2025-06-27 | 592.11x |
| 2025-06-26 | 575.02x |
| 2025-06-25 | 592.11x |
| 2025-06-24 | 523.73x |
| 2025-06-23 | 510.91x |
| 2025-06-20 | 575.02x |
| 2025-06-18 | 559.63x |
| 2025-06-17 | 571.60x |
| 2025-06-16 | 566.47x |
| 2025-06-13 | 576.72x |
| 2025-06-12 | 604.07x |
| 2025-06-11 | 604.93x |
| 2025-06-10 | 607.49x |
| 2025-06-09 | 576.72x |
| 2025-06-06 | 581.00x |
| 2025-06-05 | 604.93x |
| 2025-06-04 | 604.93x |
| 2025-06-03 | 579.29x |
| 2025-06-02 | 592.96x |
| 2025-05-30 | 562.19x |
| 2025-05-29 | 547.67x |
| 2025-05-28 | 551.08x |
| 2025-05-27 | 569.89x |
| 2025-05-23 | 573.31x |
| 2025-05-22 | 526.30x |
| 2025-05-21 | 466.47x |
